Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.25692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of a dedicated venous stent for the treatment of iliofemoral venous obstruction: A single center experience.
Vascular
December 2024
Department of Vascular Surgery, Xiamen Branch of Zhongshan Hospital, Fudan University, Xiamen, China.
Background: Endovascular recanalization with venous stenting is the preferred treatment for iliofemoral venous obstruction. We reviewed our institutional experience and mid-term outcomes with endovascular therapy for iliofemoral venous obstruction using the Venovo Self-expanding Venous Stent (BARD Peripheral Vascular, Inc., Tempe, AZ, USA).
View Article and Find Full Text PDFTricuspid Regurgitation in a Patient with Heart Transplant: Percutaneous Management.
Rev Med Chil
March 2024
Department of Cardiology, Instituto Nacional del Tórax, Santiago, Chile.
Tricuspid regurgitation (TR) is the most frequent valvular complication after heart transplantation with different clinical sequelae. In its most severe form, it can cause right heart failure with a poor long-term prognosis. Its management is complex, both medical, surgical, and percutaneous.
View Article and Find Full Text PDFFatigue Test Method to Evaluate the 50 Year Durability of Venous Stents.
Eur J Vasc Endovasc Surg
October 2024
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Objective: Iliofemoral venous obstructive disease can result in significant, potentially debilitating symptoms that can negatively affect quality of life. Unlike arterial disease, patients with deep venous disease have a significantly lower median age, therefore the need for long term stent patency becomes a matter of decades rather than years. Furthermore, iliofemoral lesions frequently require stent placement across the inguinal ligament.
View Article and Find Full Text PDFTransfemoral-only transcatheter aortic valve replacement: A single center experience of 400 consecutive patients.
Catheter Cardiovasc Interv
July 2024
Heart Center Lucerne, Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland.
Background: In transcatheter aortic valve replacement (TAVR), transfemoral (TF) access offers several advantages over alternative access routes. Advances in sheaths and valve delivery technology have catalyzed the feasibility of TF-TAVR, even in challenging anatomies.
Aims: Report procedural characteristics and outcomes of a TAVR program aiming for a 100% TF access rate.
Single suture-mediated closure system after transfemoral transcatheter aortic valve implantation: A single-center real-world experience.
Catheter Cardiovasc Interv
June 2024
Interventional Cardiology Service, "Montevergine" Clinic, GVM Care & Research, Mercogliano, Italy.
Background: Despite the use of two crossed Perclose ProGlide™ (Abbott Vascular Devices) is the most widespread technique to close the main arterial access in transfemoral transcatheter aortic valve implantation (TF-TAVI), the safest and most effective strategy still remains much debated.
Aims: The aim of the present study was to evaluate the performance of a single Perclose ProGlide suture-mediated closure device to obtain femoral hemostasis after sheathless implantation of self-expanding transcatheter heart valves through their 14 F-equivalent fix delivery systems.
Methods: This prospective observational study included 439 patients undergoing TF-TAVI at the "Montevergine" Clinic of Mercogliano, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!